Skip to main content
    P

    Protagenic Therapeutics (PTIX)

    Official site

    BIOTECHNOLOGY

    $0.46
    -0.01 (-2.52%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Protagenic Therapeutics (PTIX) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Protagenic Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was $1.37M, operating cash flow was -$2.81M and free cash flow was -$2.81M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$667.19K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $4.50M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$0N/AN/AN/AN/A
    Dec 2025N/AN/AN/AN/AN/A
    Mar 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, net income was positive. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Dec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$37.72K$1.02M$0$0$0$0$0$0$347
    Gross profit$0-$37.72K-$1.02M$0$0$0$0$0$0-$347
    Research and development$901.90K$1.70M$376.74K$3.94M$3.32M$1.59M$1.14M$699.80K$807.95K$881.19K
    Operating income-$4.50M-$5.83M-$2.59M-$5.70M-$4.53M-$3.56M-$4.14M-$2.55M-$2.09M-$2.31M
    Net income$1.37M-$5.16M-$3.59M-$5.53M-$5.00M-$3.56M-$4.52M-$2.55M-$1.75M-$2.56M
    EBITDA$5.60MN/A-$1.95M-$5.52MN/A-$3.49M-$3.63M-$2.14M-$1.74M-$2.31M
    Fiscal years ended Dec 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating income-$670.60K-$961.25K-$925.10K-$1.11M-$1.21M-$1.45M-$401.40K-$355.37K-$1.67M-$1.74M-$1.21M-$1.43M
    Net income-$667.19K-$963.62K$2.21M-$869.50K-$5.06M-$1.44M-$850.29K-$582.39K-$1.61M-$1.72M-$1.68M-$1.40M
    Last 12 quarters

    Balance Sheet

    Annual

    Line itemMar 2026Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$3.65M$2.13M$1.96M$4.32M$8.04M$11.06M$879.25K$842.27K$696.88K$1.78M
    Current assets$1.54M$2.30M$1.88M$4.20M$8.04M$11.06M$879.25K$841.98K$696.27K$1.78M
    Cash and equivalentsN/A$2.21M$1.84M$1.29M$215.19K$541.17K$671.09K$798.62K$362.49K$399.69K
    Total liabilities$1.03M$6.82M$942.76K$655.25K$1.12M$631.82K$2.03M$1.48M$907.77K$561.69K
    Short-term debt$0$3.16MN/AN/A$344.23K$0N/AN/A$0$0
    Long-term debtN/AN/AN/AN/AN/A$132.28K$1.37M$279.37K$0$0
    Shareholder equity$2.62M-$4.69M$1.01M$3.67M$6.92M$9.94M-$1.15M-$634.37K-$210.88K$1.22M
    Fiscal years ended Dec 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.27M$2.80M$3.65M$4.43M$5.00M$2.80M$89.09K$1.96M$1.51M$1.47M$2.58M$4.32M
    Total liabilities$1.15M$1.07M$1.03M$6.82M$9.70M$1.07M$5.04M$942.76K$789.32K$674.56K$446.10K$655.25K
    Cash and equivalents$2.21M$2.72MN/A$2.21M$2.72M$4.10M$14.53K$1.84M$1.06M$924.60K$831.78K$1.29M
    Shareholder equity$1.12M$1.72M$2.62M-$2.39M-$4.70M$1.72M-$4.95M$1.01M$719.01K$792.52K$2.13M$3.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Dec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$2.81M-$4.14M-$1.77M-$4.22M-$3.70M-$1.99M-$2.80M-$1.35M-$487.99K-$1.07M
    Capital expenditures$3.30K$3$0$0$149.78K$1.80K$0$0$0$0
    Free cash flow-$2.81M-$4.14M-$1.77M-$4.22M-$3.85M-$2.00M-$2.80M-$1.35M-$487.99K-$1.07M
    Investing cash flow$629.88K$943.18K$0$2.80M$4.78M$1.60M-$9.91M$0$250.00K$1.05M
    Financing cash flow$3.87M$4.51M$1.81M$1.96M$0$0$12.58M$1.22M$670.00K$670.00K
    Fiscal years ended Dec 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$488.89K-$944.30K$265.53K-$509.67K-$353.64K-$1.75M-$1.07M-$353.64K$504.15K-$1.55M-$1.66M-$1.14M
    Capital expendituresN/AN/AN/A$6$3$3$3$0$0$0$5$93.97K
    Free cash flowN/AN/AN/A-$509.67K-$353.64K-$1.75M-$1.07M-$353.64K$504.15K-$1.55M-$1.66M-$1.24M
    Last 12 quarters

    Frequently Asked Questions About PTIX

    What is Protagenic Therapeutics' annual revenue?

    Protagenic Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026.

    Is Protagenic Therapeutics profitable?

    Yes. Protagenic Therapeutics reported net income of $1.37M for the fiscal year ended Mar 31, 2026.

    How much free cash flow does PTIX generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$2.81M minus capital expenditures of $3.30K produced free cash flow of -$2.81M.

    How much debt does Protagenic Therapeutics have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $0.